Taxane-based chemotherapy combined with lapatinib results in shorter progression-free survival (PFS) than with trastuzumab as first-line treatment for patients with HER2+ metastatic breast cancer, according to an interim analysis of an open-label phase 3 randomized study presented at the 2012 Annual Meeting of the American Society of Clinical Oncology.
Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with breast cancer.
After participating in this educational activity, participants should be better able to:
Identify patients whose tumors overexpress HER2 and who have received prior therapy, including EGFR- and HER2 receptor tyrosine kinases.
Assess first-line treatment for patients with HER2+ metastatic breast cancer based on recently released randomized controlled trials.